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ABSTRACT
Objective Dendritic cells (DC) mediate intestinal
immune tolerance. Despite striking differences between
the colon and the ileum both in function and bacterial
load, few studies distinguish between properties of
immune cells in these compartments. Furthermore,
information of gut DC in humans is scarce. We aimed to
characterise human colonic versus ileal DC.
Design Human DC from paired colonic and ileal
samples were characterised by flow cytometry, electron
microscopy or used to stimulate T cell responses in a
mixed leucocyte reaction.
Results A lower proportion of colonic DC produced
pro-inflammatory cytokines (tumour necrosis factor-α
and interleukin (IL)-1β) compared with their ileal
counterparts and exhibited an enhanced ability to
generate CD4+FoxP3+IL-10+ (regulatory) T cells. There
were enhanced proportions of CD103+Sirpα− DC in the
colon, with increased proportions of CD103+Sirpα+ DC
in the ileum. A greater proportion of colonic DC subsets
analysed expressed the lymph-node-homing marker
CCR7, alongside enhanced endocytic capacity, which
was most striking in CD103+Sirpα+ DC. Expression of
the inhibitory receptor ILT3 was enhanced on colonic
DC. Interestingly, endocytic capacity was associated with
CD103+ DC, in particular CD103+Sirpα+ DC. However,
expression of ILT3 was associated with CD103− DC.
Colonic and ileal DC differentially expressed skin-homing
marker CCR4 and small-bowel-homing marker CCR9,
respectively, and this corresponded to their ability to
imprint these homing markers on T cells.
Conclusions The regulatory properties of colonic DC
may represent an evolutionary adaptation to the greater
bacterial load in the colon. The colon and the ileum
should be regarded as separate entities, each comprising
DC with distinct roles in mucosal immunity and
imprinting.
INTRODUCTION
The GI tract is in contact with numerous com-
mensal microbiota and diverse pathogens, and
therefore a balance needs to be maintained between
immunogenic and tolerogenic immune responses.
Dendritic cells (DC) are antigen-presenting cells
(APC) that mediate intestinal immune tolerance
and ensure that inflammation does not ensue in the
healthy gut, despite constant exposure to bacteria
and other stimuli (reviewed in1). The antigen sam-
pling role of DC and macrophages, via expression
of pattern recognition receptors (PRRs), enables
them to determine types of immune responses that
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Significance of this study
What is already known on this subject?
▸ The GI tract is in contact with numerous
commensal microbiota and food antigens, thus
mechanisms to generate immune tolerance to
these antigens are necessary to prevent
inflammation in the healthy gut.
▸ Intestinal CD103+ dendritic cells (DC) generate
regulatory T cell (T-reg) responses in mice and
comprised CD11b+ and CD11b− DC subsets,
with human equivalents being CD103+Sirpα+
and CD103+Sirpα− DC.
▸ The colon and the ileum have very different
functions with a much more extensive bacterial
load in the colon.
▸ Few studies distinguish between properties of
immune cells between the colon and the ileum,
and information regarding human intestinal DC
in general is scarce.
What are the new findings?
▸ There is a lower proportion of DC producing
pro-inflammatory cytokines in the human colon
compared with the (paired) ileum and colonic
DC exhibit an enhanced ability to generate
CD4+FoxP3+IL-10+ T cells (T-reg).
▸ A greater proportion of colonic DC express the
lymph-node-homing marker CCR7 alongside
enhanced endocytic capacity for bacterial
sampling; this difference was most striking in
CD103+Sirpα+ DC.
▸ Colonic DC exhibit enhanced expression of the
inhibitory receptor ILT3 associated with
tolerogenic antigen-presenting cells; this
expression was mainly restricted to CD103− DC.
▸ Colonic and ileal DC demonstrate differential
abilities to imprint homing properties on
stimulated T cells.
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are generated against a variety of intestinal antigens. DC are
unique in their ability to drive primary T cell responses;2 in the
gut, primary T cell responses directed against intestinal antigens
are generated in the mesenteric lymph nodes (MLN) and Peyer’s
patches (PP). Intestinal DC from the gut lamina propria (LP)
recognise and respond to bacteria and bacterial products from
the gut lumen, transport bacterial antigens into MLN3 4 and
maintain the delicate balance in the gut between immunogen-
icity against invading pathogens and tolerance of the commensal
microbiota (reviewed in1 5). Another property of DC is their
ability to imprint homing properties on T cells that they stimu-
late in lymphoid tissue, in order to localise immune responses
to specific tissues.6–8
Intestinal DC in the steady state are generally hyporesponsive
to toll-like receptor (TLR) ligation,9 10 constitutively produce
the anti-inflammatory cytokine interleukin (IL)-1011 and main-
tain immune tolerance in the gut by generation and mainten-
ance of regulatory T cell (T-reg) responses directed against food
antigens and commensal bacteria.12 13 This process prevents
unnecessary inflammation and hypersensitivity. In mice, the
ability of gut DC to generate gut-specific T-reg is enhanced in
the CD103 (αE integrin)
+ DC subset. CD103+ DC migrate to
MLN in afferent lymph,14 15 and in the steady state this consti-
tutive migration generates T-reg responses against harmless
luminal antigens and establishes oral tolerance.1 12–14 Human
studies involving DC isolated from MLN indicate that some of
the unique functional properties of intestinal CD103+ DC in
mice are conserved in humans.14 16 Intestinal CD103+ DC in
both mice and humans express indoleamine 2,3-dioxygenase
(IDO), an enzyme which enhances T-reg development and that
is required for the establishment of immune tolerance in the
gut.17 IDO is induced by IL-27 at intestinal sites and contributes
to growth inhibition of intestinal bacteria.18
CD103+ DC can be further characterised by their coexpression
of CD11b; CD103+CD11b+ and CD103+CD11b− DC require
different genetic factors for their development,19 and although
both subsets can induce Tcell responses of both inflammatory and
tolerising natures, recent studies suggest these DC subsets may
have distinct roles in intestinal immune homeostasis (reviewed
in20 21). However, the specific functions of these DC subsets in
immune tolerance in particular are unclear. Equivalent subsets of
CD103+Sirpα+(CD11b+) and CD103+Sirpα−(CD11b−) DC
in the human small intestine (ileum) have recently been identi-
fied,22–24 but whether these subsets are present in the human
colon had not previously been demonstrated.
The colon and the ileum have different functions, the main
function of the colon being extraction of water and salt from
solid wastes and the ileum being absorption of nutrients and
minerals in food. The bacterial load in the ileum ranges from
104 to 108 CFU/mL; however, the colon is much more heavily
colonised with a bacterial load of 1011 to 1012 CFU/mL.25 26
Despite these differences both in function and bacterial colon-
isation, there are few studies that distinguish between properties
of immune cells in these compartments. Furthermore, informa-
tion regarding properties of intestinal DC in either compart-
ment in humans is scarce, and the majority of murine data
refers to the ileum or organised lymphoid tissue.
Identification of intestinal DC is controversial; different labora-
tories use different markers to identify DC. Many different cell
types in the gut mucosa express CD11c and HLA-DR/major histo-
compatibility complex (MHC) class II, which various groups use
as a basis for DC characterisation. However, other studies have
indicated that most of these cells are not genuine DC.27 28 DC
expressing CX3-chemokine receptor 1 (CX3CR1),
29 a molecule
essential for the ability of cells to extend transepithelial projections
into the gut lumen,30 have been described in mice30 but the iden-
tity of murine CD11c+CX3CR1
+ cells as bona fide DC has been
challenged by studies demonstrating MФ-like vacuolar systems of
these ‘DC’31 and their poor ability to drive naive Tcell stimulation
and differentiation,31 15 as well as their inability to migrate to
MLN.15 It has recently been determined that all CX3CR1
hi MHC
class II+ cells in the murine gut are in fact macrophages. Within a
smaller population of CX3CR1
int cells, only a fraction of these are
bona fide DC.29 In this study, we have successfully characterised
DC from the human colon and ileum. We find that DC derived
from the colon exhibit enhanced regulatory properties and func-
tions compared with their paired, ileal counterparts. Furthermore,
we show differences between the proportions and functions of
CD103+Sirpα+ and CD103+Sirpα− DC in the human colon and
ileum. We demonstrate that the enhanced regulatory properties of
total colonic DC are due to intrinsic differences in specific DC
subsets rather than shifts in proportions of regulatory DC popula-
tions between colonic and ileal compartments.
This study demonstrates that the colon and the ileum each
comprised DC with distinct roles in mucosal immune homeosta-
sis and imprinting, and should be regarded as separate entities.
MATERIALS AND METHODS
Tissues and cells
Intestinal biopsies were obtained from the colon and the terminal
ileum in each patient, at colonoscopy from healthy controls,
following informed consent. These patients had macroscopically
and histologically normal intestines. Biopsies were collected in
complete medium. Cells were obtained from biopsy tissue by a
cell migration/’walkout’ assay during overnight incubation (37οC,
5% CO2, high humidity). DC from ‘walkout’ cells were identified
as CD45+SSClo-med HLA-DR+lineage cocktail (CD3/CD14/
CD16/CD19/CD34)− CD11c+CD64− cells by flow cytometry
(figure 1). Confirmatory experiments were carried out to
compare CD103 expression on colonic DC using the ‘walkout’
method compared with collagenase digestion; there were no dif-
ferences in the proportion of CD103+ DC using these two
methods (see online supplementary figure S1). Confirmatory
experiments were also carried out to confirm CD64 antibody
staining is positive on HLA-DR+Linmed cell populations (see
online supplementary figure S2). DC were analysed for surface
phenotype, cytokine production and phagocytosis capacity. In
other experiments, total walkout cells were enriched for DC by
centrifugation (600 g, 15 min at room temperature) over
NycoPrep and used for T cell stimulation. These intestinal-
derived DC have been characterised previously as functional
intestinal DC.32
Significance of this study
How might it impact on clinical practice in the
foreseeable future?
▸ The colon and the ileum contain DC with distinct roles in
mucosal immunity. Targeting factors determining the
inflammatory or activation state of intestinal DC within
separate compartments will allow manipulation and
generation of regulatory DC aimed at immunomodulatory
therapy for inflammatory disease with tissue
compartmentalisation.
Mann ER, et al. Gut 2016;65:256–270. doi:10.1136/gutjnl-2014-307916 257
Gut immunity
Figure 1 Expression of CD103 and
Sirpα on human colonic and ileal
dendritic cells (DC). (A) Identification
of human gut DC according to FACS
dot plot of lineage cocktail (CD3/CD14/
CD16/CD19/CD34) versus HLA-DR
(following identification of live cells as
CD45+ dead cell exclusion dye− cells)
and subsequent CD11c versus CD64
dot plots. (B) Following DC
identification as HLA-DR+lineage
cocktail− CD11c+CD64− cells,
expression of CD103 and Sirpα was
analysed. Dot plot quadrants were set
according to comparison with
isotype-matched controls; FACS dot
plots demonstrating expression of
CD103 and Sirpα on human colonic
and ileal DC. (C) Summary graph
demonstrating proportions of
CD103+Sirpα+, CD103+Sirpα− and
CD103−Sirpα+ DC in the human colon
and ileum (n=12) (D) Summary graphs
showing proportions of CD103+Sirpα+
and CD103+Sirpα− DC in all
experiments (n=12). Paired t test was
applied in all cases: *p<0.05;
**p<0.01; ***p<0.001.
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Human peripheral blood was collected from healthy volun-
teers with no known autoimmune or inflammatory diseases,
allergies or malignancies, following informed consent.
Enrichment of CD4+ naive T cells
Peripheral blood mononuclear cells (PBMC) from healthy
control blood were obtained by centrifugation over Ficoll-Paque
Plus (Amersham Biosciences, Chalfont St. Giles, UK). PBMC
were suspended in MiniMACS buffer (phosphate-buffered
saline (PBS) containing 0.5% bovine serum albumin and 2 mM
ethylenediaminetetraacetic acid) and CD4+ naive T cells were
enriched by depletion of CD14+, CD19+, HLA-DR+, CD8+
and CD45RO+ cells with immunomagnetic beads (Miltenyi
Biotech, Bisley, UK) following the manufacturer’s instructions.
Purity was >95% in all cases.
T cell proliferation assay
Carboxyfluorescein succinimidyl ester (CFSE, Invitrogen,
UK)-labelled CD4+ naive T cells (4×105/well) were incubated
for 5 days in U-bottomed 96-well microtiter plates with
enriched allogeneic DC at 0%, 1%, 2% or 3% in a mixed leuco-
cyte reaction. Cells were recovered and CFSElo proliferating
cells identified and quantified by flow cytometry.
Antibody labelling
Monoclonal antibodies with the following specificities and con-
jugations were used: CD103-fluorescein isothiocyanate (FITC)
(BER-ACT8), IL-12 FITC/PE (C11.5), T-bet-PE (4B10),
FoxP3-PE (259D/C7), IL-17A-PE (SCPL1362), integrin β7-PE
(FIB504), CD34-PeCy5 (581), CD4-PeCy5 (RPA-T4), HLA-DR-
APC (G46-6), IFN-γ-APC (B27), IL-10-APC ( JES5-19FI) and
IL-4-PeCy7 (8D4-8) were purchased from BD Biosciences
(Oxford, UK); TLR2-FITC (TLR2.3), TLR4-FITC (HTA125),
CD40-FITC/PE (LOB7/6), CD3-PeCy5 (S4.1), CD14-PeCy5
(TUK4), CD16-PeCy5 (3G8), CD19-PeCy5 (SJ25-C1) and
tumour necrosis factor (TNF)-α-APC (MP9-20A4) were pur-
chased from AbD Serotec (Oxford, UK); TNF-α-FITC
(MAb11), IL-1β-FITC (B-A15), CD68-PE (Y1/82A) and IL-22-
PeCy7 (22URTI) were purchased from eBioscience (Hatfield,
UK); CX3CR1-PE (528728), ILT3-PE (293263), TGFβ1-PE
(27232), CCR9-PE (248621), CCR7-PE/PeCy7 (2H4) and
CCR4-APC (205410) were purchased from R&D Systems
(Abingdon, UK); CD64-PeCy7 (10.1) was purchased from
Biolegend (London, UK). Appropriate isotype-matched control
antibodies were purchased from the same manufacturers. After
the staining, cells were fixed with 1% paraformaldehyde in
0.85% saline.
Cytokine analysis
The intracellular cytokine production by DC was measured by
comparing cells incubated without monensin (controls) from
those incubated in the presence of monensin for 4 h.
Flow cytometry and data analysis
Data were acquired on FACSCanto II and LSR II machines (BD
Biosciences) and analysed using FlowJo (Treestar).
Endocytic activity of DC
Endocytic activity of DC was determined by uptake of
FITC-dextran (molecular weight=40 kDa) (Sigma-Aldrich, UK).
Briefly, cells were incubated with 1 mg/mL FITC-dextran for
30 min at either 37 or 4°C (on ice; internal control), and then
washed in PBS. Surface staining for flow cytometry was then
performed.
Electron microscopy
Tissue was fixed in 3% glutaraldehyde and 1% osmium tetrox-
ide, then washed and block stained with 2% uranyl acetate. The
samples were then dehydrated using an acetone gradient and
gradually infiltrated with araldite resin. Sections (100 nm) were
cut on a Reichert-Jung Ultracut E microtome and collected on a
200 mesh copper grid. The grid was stained with Reynold’s lead
citrate, carbon coated and visualised using a JEOL 1200 EX
electron microscope.
Statistical analysis
Two-way and one-way repeated measures analysis of variance
and two-tailed paired tests were applied as stated in the figure
legends. In the case of multiple comparisons, subsequent ad hoc
Bonferroni correction was applied. p<0.05 was considered stat-
istically significant.
RESULTS
Characterisation of CD103+ DC subsets in the human colon
and ileum
Human intestinal DC were identified as HLA-DR+/lineage cocktail
(CD3/CD14/CD16/CD19/CD34)− CD11c+CD64− cells by flow
cytometry (figure 1A). Identifying human intestinal DC in this
manner enabled analysis, characterisation and comparison of DC
within separate intestinal compartments. In mice, regulatory DC
capable of generating T-reg responses express CD103 and migrate
to lymphoid tissue.1 12–14 However, the regulatory functions of
specific intestinal CD103+ DC subsets in mice, including
CD103+CD11b− and CD103+CD11b+ DC, are unclear. Recently
identified equivalent subsets in the human small intestine (ileum)
have been determined including CD103+Sirpα+ DC (representing
murine CD103+CD11b+ DC) and CD103+Sirpα− DC (represent-
ing murine CD103+CD11b− DC).22–24 However, such subsets in
the human colon previously remained to be characterised.
To this end, we compared expression of CD103 and Sirpα on
human gut DC within both colonic and ileal compartments.
Both human colonic and ileal DC expressed CD103, and the
majority of these CD103+ DC co-expressed Sirpα in both cases
(figure 1B, C). However, there was a greater proportion of
CD103+Sirpα+ DC in the ileum, alongside enhanced propor-
tions of CD103+Sirpα− DC in the colon (figure 1C, D). There
was no change in the proportions of CD103−Sirpα+DC
between colonic and ileal compartments (figure 1C). Due to the
small proportions and numbers of CD103+Sirpα− DC in all
cases, further phenotypic analysis of this DC subset was not pos-
sible. These results indicate differences in the proportions of
CD103+ DC subsets, but not CD103− DC exist between
colonic and ileal compartments of the human gut.
Enhanced expression of the lymph-node-homing marker
CCR7 on human CD103+Sirpα+ DC in the colon
In mice, CD103+ DC migrate to MLN in afferent lymph.14 15 In
the steady state, this constitutive migration generates tolerogenic T
cell responses against harmless luminal antigens and establishes
oral tolerance.1 12–14 Both CD103+ and CD103− DC from the
colon displayed enhanced CCR7 expression (figure 2A).
Furthermore, a striking difference in proportions of CCR7 expres-
sion was observed upon comparison of CD103+Sirpα+ DC
between the colon and the ileum, with a greater proportion of
CCR7+ DC within this DC subset in the colon (figure 2B; there
were not enough cell numbers to analyse CCR7 expression on
CD103+Sirpα− DC). These data suggest a more migratory role for
colonic DC compared with their ileal counterparts.
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Figure 2 Expression of CCR7 on
human colonic and ileal dendritic cells
(DC) subsets. (A) FACS dot plots
demonstrating expression of CD103
and co-expression of lymph-node-
homing marker CCR7 on colonic and
ileal DC. Dot plot quadrants were set
according to comparison with isotype-
matched controls. Summary graphs
representing CCR7 on all DC, CD103+
DC and CD103− DC (n=6 in all cases).
(B) FACS dot plots demonstrating
expression of CCR7 on CD103+Sirpα+
DC on colonic and ileal DC and
summary graph representing CCR7 on
CD103+Sirpα+ DC (n=6). Paired t test
was applied in all cases: *p<0.05;
**p<0.01; ***p<0.001.
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Human colonic DC display enhanced endocytic capacity
compared with equivalent ileal DC
We next wanted to determine whether the increased migratory
potential of DC in the colon (via CCR7 expression) corre-
sponded with differences in antigen uptake (endocytic) capacity.
To this end, we tested the ability of human intestinal DC to endo-
cytose FITC-dextran. We found that a greater proportion of total
DC from the colon displayed an endocytic capacity compared
with their ileal counterparts (figure 3A, B). Interestingly, in both
intestinal compartments, the majority of FITC-dextran+ DC
were CD103+ (figure 3A, D).
However, enhanced endocytic function was observed in both
CD103+ and CD103− colonic DC subsets compared with their
ileal counterparts (figure 3A, D). Analysis of CD103+Sirpα+
DC showed enhanced endocytic capacity by this DC subset in
the colon compared with their ileal equivalents (figure 3C, D).
Furthermore, CD103+Sirpα+ DC had a greater endocytic func-
tion compared with other DC subsets in both colonic and ileal
compartments (figure 3D).
Thus, taken with data above demonstrating enhanced expres-
sion of CCR7 by colonic CD103+Sirpα+ DC in particular,
these data strongly suggest a role for antigen-sampling and
steady-state migration to lymphoid tissue by this DC subset.
Furthermore, the enhanced endocytic capacity of DC subsets in
the colon suggests a greater role for colonic DC in this process.
Higher levels of the inhibitory receptor ILT3 on colonic DC
ILT3 is an inhibitory receptor expressed on myeloid APC.33
High levels of ILT3 expression have been shown to render
APC tolerogenic,34 35 with at least some of the inhibitory
effects of ILT3 being mediated through suppression of T cell
responses.36 37 To determine whether there was a difference in
the potential inhibitory properties of colonic and ileal DC
subsets, we determined the expression of ILT3 on DC from
these compartments. There was a greater proportion of total
DC from the colon expressing ILT3 compared with their ileal
counterparts (figure 4A). However, levels of expression of
ILT3 per cell as assessed by fluorescence intensity were not
Figure 3 Uptake of fluorescein isothiocyanate (FITC)-dextran as a measure of endocytosis by colonic and ileal dendritic cells (DC). (A) FACS dot
plots demonstrating endocytosis of FITC-labelled dextran over 30 min at 4°C (control) and 37°C (test) by colonic and ileal CD103+ and CD103− DC.
Dot plot quadrants were set according to comparison with control staining (4°C) as demonstrated. (B) Summary graph demonstrating FITC-dextran
uptake by total DC (n=6). (C) FACS dot plots demonstrating endocytosis of FITC-labelled dextran by CD103+Sirpα+ DC at 4°C (control) and 37°C
(test) within colonic and ileal compartments (n=3). (D) Summary graph representing FITC-dextran uptake by CD103+, CD103− and CD103+Sirpα+ DC
within colonic and ileal compartments (n=3). Paired t test was applied in all cases: *p<0.05; **p<0.01; ***p<0.001.
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significantly different between total colonic and ileal DC
(figure 4B).
Upon analysis of specific DC subsets, we determined that
CD103− DC were the major DC subset expressing ILT3, with
both proportions of positive cells and levels of expression per cell
being greater than that of CD103+ DC in both intestinal compart-
ments (figure 4A, C). Strikingly, proportions of CD103− DC
expressing ILT3 were enhanced in the colon, alongside enhanced
levels of expression of ILT3 per cell (figure 4D). However, propor-
tions of both CD103+ DC (figure 4E) and CD103+Sirpα+ DC
(figure 4F) expressing ILT3 were also enhanced in the colon,
although there was no change in the levels of ILT3 expression per
cell compared with ileal DC in these DC subsets. Given the regula-
tory properties associated with this receptor, the enhanced expres-
sion on colonic DC supports a more regulatory role for these cells
versus their ileal counterparts.
DC maturation and activation is equivalent in the colon and
the ileum
Intestinal DC characteristically express low levels of TLRs com-
pared with blood DC, thought to contribute to hyporesponsive-
ness to the gut microbiota in the steady state.11 To determine
potential differences in colonic versus ileal ability to sense bacteria
and microbial products, we analysed expression of TLRs 2 and 4,
and also expression of DC activation marker CD40 (a marker that
we have to enhance on gut DC in inflammation38). We found that
there were no differences in expression of these molecules, com-
paring DC from colonic and ileal tissue (figure 5A), suggesting
there were no differences in DC maturation and activation
between colonic and ileal compartments. To further analyse the
maturation state of DC, we used electron microscopy (EM) to
analyse DC morphology. Immature and mature DC, as assessed by
length of veiled protrusions,39 were detected from the colon and
the ileum, as were macrophage-like cells with an extensive vacu-
olar network. These observations demonstrated there were no dif-
ferences in proportions of mature DC or macrophage-like cells.
However, there was an enhanced proportion of morphologically
immature DC in the ileum (figure 5B).
Enhanced proportion of pro-inflammatory cytokine
producing DC in the ileum
Given the different functions and antigenic load of the colon and
the ileum, we investigated whether immunological functions of
these compartments differed, specifically regarding DC. Arguably,
Figure 4 Expression of the inhibitory receptor ILT3 on colonic and ileal dendritic cells (DC). (A) FACS dot plots demonstrating expression of ILT3 on
colonic and ileal CD103+ and CD103− DC. Dot plot quadrants were set according to isotype-matched controls. Summary graph demonstrating
proportions of ILT3+ (total) DC from colon and ileum (n=8). (B) Summary graph demonstrating levels of expression (mean fluorescence intensity
(MFI)) of ILT3 on colonic and ileal DC (n=8). (B) Summary graphs representing proportion of ILT3+ DC and levels of ILT3 expression (MFI) on CD103+
compared with CD103− DC (n=8) in the colon and the ileum. (D) Summary graphs representing the proportion of CD103− DC expressing ILT3 and
levels of ILT3 expression on CD103− DC (n=8). (E) Summary graphs representing the proportion of CD103+ DC expressing ILT3 and levels of ILT3
expression on CD103+ DC (n=8). (F) FACS dot plots demonstrating ILT3 expression on CD103+Sirpα+ DC, and summary graphs representing
proportions of CD103+Sirpα+ DC expressing ILT3 and levels of ILT3 expression on this DC subset (n=8). Paired t test was applied in all cases:
*p<0.05; **p<0.01; ***p<0.001.
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the most important function of DC is their unique ability to gener-
ate primary T cell responses. DC ability to polarise specific types
of T cell responses is in part due to DC production of specific
T cell polarising cytokines. To this end, prior to analysis of DC
ability to generate types of T cell responses, we determined
whether there were differences between colonic and ileal DC in
the production of regulatory or pro-inflammatory cytokines.
Intracellular cytokine production by total DC within colonic
and ileal compartments following monensin incubation was
detected via comparison to non-monensin-treated controls
(figure 6A). Although production of all measured cytokines was
low from all DC aside from TGF-β and TNF-α (figure 6B),
a greater proportion of ileal DC produced the pro-inflammatory
cytokines TNF-α and IL-1β compared with colonic DC
Figure 4 Continued.
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(figure 6B, C). These results suggest a more inflammatory role
for ileal DC compared with colonic DC. There were no differ-
ences in production of TGF-β, IL-12, IL-23 or IL-22
(figure 6B). Further DC subsets were not analysed due to diffi-
culties in obtaining sufficient cell numbers for culture ± monen-
sin to study cytokine production.
Colonic DC have a greater potential to generate regulatory
T cells compared with ileal DC
We next determined whether the potentially greater regulatory
properties of colonic DC compared with ileal DC and enhanced
inflammatory cytokine production by ileal DC described above
translated in their ability to generate T cell responses. We used
total colonic or ileal DC (from the same individual) to stimulate
allogeneic CD4+ T cell responses in vitro (T cells isolated from
the blood of a separate, healthy donor). Dividing CD4+ T cells
were identified following DC co-culture as CFSElo CD3+ lym-
phocytes (figure 7A; pre-sorted as naive (CD45RO−-) CD4+ T
cells prior to culture). Both colonic and ileal DC stimulated
dose-dependent proliferation of CFSE-labelled T cells during
5 days of in vitro culture (figure 7A). We determined cytokine
production and transcription factor (TF) expression from stimu-
lated T cells post-culture and found that the predominant cyto-
kines/TF produced by T cells stimulated by either colonic or
ileal DC were IL-10 and T-bet (figure 7B). Although there were
no differences in colonic or ileal DC ability to drive production
of Th1/Th17 TF/cytokines measured (IFN-γ, TNF-α, T-bet,
IL-17A) or Th2/regulatory cytokines measured (IL-10, IL-4,
TGF-β) (figure 7B), colonic DC generated a greater proportion
of CD4+FoxP3+IL-10-producing (regulatory) T cells compared
with ileal DC (figure 7C). Taken with the regulatory properties
of colonic DC described above, these data suggest colonic DC
may play a greater role in intestinal immune tolerance compared
with ileal DC.
Differential homing marker expression on colonic and ileal
DC corresponds with their ability to imprint homing markers
on T cells
In mice, T cells generated by intestinal DC expressed
gut-homing marker α4β7 and small-bowel-homing marker
Figure 5 Dendritic cells (DC) maturation and activation in the colon and the ileum. (A) Summary graphs representing toll-like receptor 2 (TLR2) (n=9),
TLR4 (n=9) and CD40 (n=8) expression on colonic and ileal DC, as assessed by flow cytometry (n). (B) Electron micrograph pictures demonstrating types of
DC present in the colon and the ileum: examples show short-veiled (immature) DC and long-veiled (mature) DC, and macrophage-like cells with an
extensive vacuolar network. Cells were counted and types of DC as a proportion of total cell numbers present was calculated and plotted on summary
graph (n=3). Paired t test was applied in all cases: *p<0.05; **p<0.01; ***p<0.001. APC, antigen-presenting cells.
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CCR9.6 7 However, the majority of murine data involves DC
derived from the small bowel or organised lymphoid tissue and
data in humans are scarce. We have previously shown that
human gut versus skin DC exhibit tissue-specific homing proper-
ties corresponding to their site of origin and the homing profile
that they imprint on T cells.40 Here, we compared the homing
receptor expression of colonic versus ileal DC and found that a
greater proportion of colonic DC expressed the skin-associated
homing marker CCR4 while their ileal counterparts preferen-
tially expressed CCR9 (figure 8A). There was no change in
expression of gut-homing marker β7 integrin (data not shown).
We then studied the ability of colonic and ileal DC to imprint
these homing markers on naive CD4+ T cells. Ileal, but not
colonic, DC were able to generate CCR9+ T cells; however, the
majority of T cells generated in both cases were CCR9− (figure
8B). Both ileal and colonic DC generated T cells expressing β7
integrin (figure 8C), but colonic DC were more able to imprint
skin-homing marker CCR4 on T cells (figure 8D). These data
demonstrate differential imprinting capacities of colonic and
ileal DC that correspond to their own patterns of homing
marker expression.
DISCUSSION
Our data demonstrate that specific functional differences exist
between gut DC derived from the human colon and ileum. We
demonstrate that regulatory properties of gut DC and their
ability to imprint specific homing profiles on T cells are depend-
ent upon their anatomical location within the gut. We demon-
strate differences between colonic and ileal compartments in
proportions and functions of human CD103+ DC subsets
(which are a migratory DC subset critical for generation of
T-regs and tolerance to the gut microbiota and food antigens in
mice.1 12–15). Our data strongly suggest a more regulatory role
for human colonic DC compared with their ileal counterparts,
with lower proportions of colonic DC producing inflammatory
cytokines and an enhanced ability to drive T-reg generation.
Expression of the inhibitory receptor ILT3, high levels of which
render APC tolerogenic,34 35 was also increased on colonic DC.
Furthermore, we demonstrate that a greater proportion of
colonic DC express the lymph-node-homing marker CCR7 and
exhibit endocytic capacity, strongly suggesting that colonic DC
have an enhanced ability to sample antigens and migrate to
lymphoid tissue to generate regulatory immune responses
Figure 6 Intracellular cytokine
production by colonic and ileal
dendritic cells (DC). (A) FACS dot plots
demonstrating production of
interleukin (IL)-1β, tumour necrosis
factor (TNF)-α, TGF-β and IL-12 by
colonic and ileal DC. Dot plot
quadrants were set according to
comparison with non-monensin
controls. (B) Summary graph
representing intracellular cytokine
production by colonic and ileal DC
(following monensin incubation)
(TGF-β: n=7; TNF-α: n=7; IL-12: n=6;
IL-1β: n=8; IL-23: n=3; IL-22: n=6).
(C) Summary graphs showing TNF-α
(n=7) and IL-1β (n=8) production by
colonic and ileal DC. Paired t test was
applied in all cases: *p<0.05;
**p<0.01; ***p<0.001.
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Figure 7 Colonic and ileal dendritic
cells (DC) ability to generate regulatory
T cells in vitro. (A) FACS dot plots
demonstrating identification of
stimulated/proliferating CD4+ naive
T cells following 5-day co-culture with
DC, via gating on blasting lymphocytes
from forward scatter versus side scatter
plot, and subsequent gating of
CD3+CFSElo cells (cells were pre-sorted
prior to culture as CD4+ naive T cells).
T cell proliferation displayed as mean
±SEM proportion of dividing T cells.
Concentration of DC was statistically
significant following two-way analysis
of variance analysis (p<0.001; n=7).
(B) FACS plots demonstrating
expression of interleukin (IL)-10 and
T-bet by dividing T cells (CD3+CFSElo
post-culture, sorted pre-culture as
CD4+ naive T cells) following culture:
quadrants were set based on
isotype-matched control (T-bet) or
non-monensin control (IL-10).
Summary graph showing mean±SEM
proportions of diving T cells producing/
expressing T-bet (n=6), tumour
necrosis factor (TNF)-α (n=5), IFN-γ
(n=7), IL-17A (n=7), IL-10 (n=7),
TGF-β1 (n=7) and IL-4 (n=7). (C) FACS
plots showing dividing T cells
(CD3+CFSElo post-culture, sorted
pre-culture as CD4+ naive T cells)
expressing FoxP3 and producing IL-10
following stimulation by either colonic
or ileal DC. Summary graph showing
all experiments (n=7). Quadrants on
dot plots were set based on
isotype-matched control (FoxP3) or
non-monensin control (IL-10). Paired t
test was applied in all cases: *p<0.05;
**p<0.01; ***p<0.001. CFSE,
carboxyfluorescein diacetate
succinimidyl.
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in vivo, compared with ileal DC. Such a function may be
important in generating tolerance to the gut microbiota, the
load of which is greatly elevated in the colon versus the ileum.
Despite the differences both in function and bacterial load of
the colon and the ileum, few studies distinguish between
immune cells in colonic and ileal compartments, and functional
information in humans is scarce in both compartments. Our
new data demonstrate that the colon and the ileum should be
regarded as separate entities, each comprising DC with distinct
roles in gut immunity.
Identification of intestinal DC in any species is challenging
due to the use of markers that do not discriminate clearly
between DC and macrophages (MФ),27 and also complicated by
the use of different markers by different laboratories to identify
APC. Here, we show successful characterisation of human intes-
tinal DC and have confirmed they do not express macrophage
Figure 8 Colonic and ileal dendritic
cells (DC) ability to imprint homing
markers on T cells. (A) FACS dot plots
demonstrating expression of CCR4 and
CCR9 on DC from the colon and the
ileum (pre-gated on CD45+viable cells
and then HLA-DR+lineage− cells).
Summary graphs showing CCR4 and
CCR9 expression by colonic and ileal
DC (n=4). (B) FACS dot plots showing
examples of CCR9 expression on
dividing T cells (CD3+CFSElo
post-culture, sorted pre-culture as
CD4+ naive T cells) following
stimulation by colonic or ileal DC, and
summary graph showing all
experiments (n=7). (C) FACS dot plots
showing examples of β7 integrin
expression on dividing T cells
(CD3+CFSElo post-culture, sorted
pre-culture as CD4+ naive T cells)
following stimulation by colonic or
ileal DC, and summary graph showing
all experiments (n=7). (D) FACS dot
plots showing examples of CCR4
expression on dividing T cells
(CD3+CFSElo post-culture, sorted
pre-culture as CD4+ naive T cells)
following stimulation by colonic or
ileal DC, and summary graph showing
all experiments (n=7). Quadrants on
dot plots were set based on
isotype-matched controls. Paired t test
was applied in all cases: *p<0.05;
**p<0.01; ***p<0.001.
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markers. We have determined that in the steady state both
human colonic and ileal DC expressed CD103, a DC subset
with tolerogenic properties in mice.41–43 The majority of
CD103+ DC in both intestinal compartments co-expressed
Sirpα, the human equivalent of murine CD103+CD11b+
DC.22 24 However, there was a greater proportion of the
double-positive CD103+Sirpα+ DC subset in the ileum, while
there were greater proportions of single-positive CD103+Sirpα−
DC (human equivalent of murine CD103+CD11b− DC) in the
colon relative to the ileum (despite CD103+Sirpα+ DC still
being the predominant subset), reflecting patterns of expression
of CD103 and CD11b in mice.21 44 A striking difference
between this murine and our human data however is illustrated
by the predominant DC subset in the murine colon being
CD103+CD11b− DC in mice.44 While in humans we show
there are indeed greater proportions of their CD103+Sirpα−
DC equivalents in the colon, this subset is still a minority subset
in the human colon and certainly not the predominant DC
subset. The significance of the increased proportions of these
DC in the colon remains to be determined. Although recent
studies suggest both murine CD103+CD11b+ and
CD103+CD11b− DC subsets may have distinct roles in intes-
tinal immune homeostasis (reviewed in20 21), the specific regula-
tory functions of these CD103+ subsets and their human
equivalents are unclear. The essential role for murine
CD103+CD11b+ DC in Th17 cell polarisation22 may suggest a
greater proportion of DC in the human ileum may generate Th17
responses. However, other studies have shown human
CD103+Sirpα+ DC are better than their CD103+Sirpα− counter-
parts at generating regulatory T cell responses in vitro.24 Further
functional studies are necessary to determine the roles of murine
and human CD103+ DC subsets in mucosal immune homeostasis
and whether the functions of these subsets may be altered under
inflammatory conditions compared with the steady state.
Although the low numbers of cells available from human
biopsy tissue did not allow us to further characterise
CD103+Sirpα− DC, we demonstrate compartment-specific dif-
ferences in specific DC subsets including CD103−(Sirpα+) and
CD103+Sirpα+ DC (as well as total CD103+ DC). Proportions
of these subsets expressing CCR7 were increased in the colon,
strongly suggesting a more migratory role for colonic DC.
Properties of gut DC in the steady state include a high endocytic
capacity due to continual sampling of antigens from the gut
lumen.11 We observed that human DC contained a greater endo-
cytic capacity in the colon versus the ileum. Taken together, the
enhanced migratory potential and endocytic capacity of colonic
DC compared with ileal DC, along with their enhanced poten-
tial to generate T-regs, may be representative of a regulatory
profile for DC in the colon. These differences between colonic
and ileal DC subsets were the most striking in CD103+Sirpα+
DC, with nearly all of this DC subset in the colon being endocy-
tic and comprising the majority of endocytic DC in either com-
partment. Only few CD103− DC displayed endocytic capacity,
supporting recent studies in mice.45 These data support previous
studies demonstrating high levels of CCR7 expression on
human CD103+Sirpα+ DC from the ileum24 and suggest an
important role for this DC subset in antigen sampling leading to
generation of T-reg responses that may be directed against the
gut microbiota in the steady state. The major phagocytic role of
CX3CR1+ mononuclear phagocytes, but not CD103+ DC,
during antigen-driven colitis in mice46 suggests CD103+ DC
may lose endocytic capacity under inflammatory conditions.
The inhibitory receptor ILT3 was expressed on all DC subsets
in both colon and ileum to some extent. However, a greater
proportion of all DC subsets expressed ILT3 in the colon versus
the ileum, supporting a regulatory role for colonic DC.
However, a much greater proportion of CD103− DC expressed
this receptor and at higher levels than CD103+ DC.
Furthermore, differences in proportions of ILT3+ DC between
the colon and the ileum were the most striking on the CD103−
(Sirpα+) DC subset, on which levels of ILT3 per cell were also
enhanced. Given the association of high levels of ILT3 with tol-
erogenic APC properties,25 26 these data suggest a novel role for
CD103− DC in intestinal immune tolerance in the steady state.
Although data regarding the homeostatic functions of intestinal
DC have been predominantly focused on CD103+ DC, recent
murine studies demonstrate CD103−CD11b+ DC (equivalent to
human CD103−Sirpα+ DC) expressing CXCL16 may indeed
play a protective role in the gut mucosa via induction of IL-22
(a cytokine critical for tissue regeneration and recovery follow-
ing infection and inflammation).47 We demonstrate that the
majority of human CD103− DC in both colonic and ileal com-
partments, like CD103+ DC, expressed CCR7, suggesting they
are a migratory cell subset. These data support murine studies
that demonstrate CD103− DC migration in afferent lymph.48
Our data demonstrate intrinsic differences in specific DC
subsets in the colon versus the ileum, supporting a more regula-
tory role for colonic DC. Indeed, the reduced proportion of
colonic DC producing pro-inflammatory TNF-α and IL-β, com-
bined with the enhanced ability of colonic DC to generate
CD4+FoxP3+IL-10+ T-reg in vitro, strongly support a more
regulatory role for colonic DC compared with their ileal coun-
terparts. Of note, TLR expression and cytokine production was
inherently low by DC in all cases, with only TGF-β, TNF-α and
IL-1β being produced at detectable levels. Even in these cases,
cytokine-producing (and TLR+) DC comprised only the minor-
ity of DC and there were little effects of lipopolysaccharide
stimulation at various doses (data not shown), supporting
studies demonstrating intestinal DC are hyporesponsive to
stimulation and involved in intestinal immune tolerance.9 10 12 49
The higher proportions of morphologically immature DC in the
ileum as detected by EM may be reflective of the reduced bac-
terial load in this intestinal compartment.
Murine DC from intestinal organised lymphoid tissue imprint
gut-homing markers α4β7 and CCR9 on T cells from different
sources, thus targeting T cells back to intestinal tissue.6–8 We pre-
viously demonstrated human gut DC generate gut-specific T cell
responses.40 However, there was previously no information avail-
able regarding compartment-specific effects of gut DC on T cell
stimulation or regarding the homing properties of the DC them-
selves. We demonstrate here that colonic and ileal DC exhibit dis-
tinct patterns of homing marker expression in terms of
chemokine receptors CCR9 (small bowel homing) and CCR4
(skin homing). Furthermore, chemokine receptor expression on
colonic and ileal DC corresponded to their ability to imprint
these same receptors on stimulated T cells, with an enhanced
ability of ileal DC to generate CCR9+(β7+) T cells compared
with colonic DC, while colonic DC imprinted CCR4 on T cells.
The differences in ileal and colonic DC ability to imprint homing
markers on T cells (including enhanced ability of colonic DC to
generate skin-homing CCR4+ T cells) have implications in IBD
with tissue compartmentalisation. Both Crohn’s disease and
ulcerative colitis are associated with increased infiltrating
gut-homing lymphocytes.50 51 Indeed, treatment with anti-gut-
homing α4β7 therapy is effective in some patients with IBD.52
Furthermore, some patients with IBD have a propensity to
develop extraintestinal manifestations affecting the skin,53 as well
as anti-TNF-induced psoriasiform skin lesions mediated by DC
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in some cases.54 Further studies may determine whether patients
with IBD with colonic inflammation as opposed to ileal inflam-
mation are more likely to develop skin manifestations such as ery-
thema nodosum and pyoderma gangrenosum. Together, our data
demonstrate, for the first time, that functional differences exist
between human intestinal DC within colonic and ileal compart-
ments of the gut. It can be speculated that the more extensive
bacterial load in the colon compared with the ileum25 26 requires
colonic APC to adopt regulatory properties, preventing
unwanted immune responses to the gut microbiota. However,
further studies are necessary to determine the role of the gut
microbiota in colonic and ileal compartments in shaping DC
function. These data provide new insight into the regulatory
functions and properties of CD103+ and CD103− gut DC
subsets in the steady state. Targeting factors that determine the
activation or inflammatory state of intestinal DC within separate
gut compartments may allow manipulation and generation of
regulatory DC, aimed at immunomodulatory therapy for inflam-
matory disease with tissue compartmentalisation.
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